Laurus Labs Limited (BOM:540222)

Market Cap	330.78B
Revenue (ttm)	52.73B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	3.70
PE Ratio	165.17
Forward PE	n/a
Dividend	0.80 (0.13%)
Ex-Dividend Date	Nov 6, 2024

Volume	31,751
Average Volume	53,859
Open	618.95
Previous Close	614.70
Day's Range	606.40 - 620.40
52-Week Range	386.85 - 646.25
Beta	n/a
RSI	59.94
Earnings Date	Apr 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,007
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.